This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The U.S. Energy Department's weekly inventory release showed a smaller-than-expected increase in natural gas supplies. Despite the headline beat, bearish weather predictions pointed to weakening demand and pressured the fuel’s price, which lost around 4% for the week.
ECR CKRGZ POOL CQP LNG CHKVP CRK COG CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP GTT CHK CHK.WI CHK.PRD
The Weekly Natural Gas Storage Report – brought out by the Energy Information Administration (EIA) every Thursday since 2002 – includes updates on natural gas market prices, the latest storage level estimates, recent weather data and other market activities or events.
ECR CKRGZ CQP LNG CHKVP CRK COG CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR CHK.PRD
Cheniere Energy, Inc. (LNG - Free Report) recently received approval from Federal Energy Regulatory Commission (FERC) to introduce fuel gas for testing Train 1 of its Corpus Christi liquefaction (CCL) project. While the fuel gas will help make the train operational, the company will seek another approval from FERC to introduce feed gas to start the process of gas liquefaction. Cheniere Energy is likely to commence gas liquefaction at Train 1 in early September and start exporting its first test cargo in December/January.
ECR CQP LNG CVRR BCEI GPRK
We issued an updated research report on Exxon Mobil Corporation (XOM - Free Report) on Jul 5, 2018. Being the largest publicly-traded energy firm, the company has a lead position in the energy industry owing to size and diversity of asset base, in terms of business mix and geographical footprint. However, the pipeline bottleneck problem is likely to dampen the company’s domestic production.
ECR APC XOM CVX AEUA
Cheniere Energy, Inc. (LNG - Free Report) , riding high on its first-mover advantage in exporting liquified natural gas from the United States, recently inked a major deal with Taiwan’s CPC Corporation. Per the deal, Cheniere Energy will supply two million tons of liquified natural gas (LNG - Free Report) annually to CPC for 25 years. Cheniere Cashing in on Shifting Trends Considering the secular shift to cleaner burning fuel for power generation worldwide and in the Asia-Pacific region in particular, Cheniere Energy is likely to cash in on the development.
ECR CQP BLT BHP LNG BHPBF BBL BHP BCEI GPRK BHPLF
June 29 (Reuters) - U.S. federal energy regulators have told Energy Transfer Partners LP to finish restoring the land around parts of its Rover natural gas pipeline in Ohio and Michigan before allowing the company to put more segments in service.
ECR RRC ETP.PRC ETP RGRYY EQT RRL AST RRS AR RGRLF ACTPF
The U.S. Energy Department's weekly inventory release showed a larger-than-expected increase in natural gas supplies. Despite the headline miss, the report pointed to a tightening supply-demand balance with growing natural gas use for air-conditioning amid relatively flat production.
ECR CKRGZ CQP LNG CHKVP CRK COG CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI HFC CHK.PRD
Exxon Mobil Corporation (XOM - Free Report) announced that its Singapore-based integrated manufacturing facility has commenced production of petrochemicals. Among all the integrated refining and petrochemical facilities operated by the company in the world, the complex in Singapore is the largest.
ECR APC XOM WRD AEUA
We initiated a research report on Matador Resources Company (MTDR - Free Report) on Jun 20. The company’s strong presence in the prospective oil and gas plays in the United States will back its production growth. However, rising operating cost is a concern.
ECR DLTR APC WRD AEUA
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET